INS and type 2 diabetes mellitus: At baseline, before the first prescription-filled claim for canagliflozin, approximately 60 % of patients (with follow-up data) had A1C levels ≥8.0 % indicating poor glycemic control and inadequate management of their T2DM, despite being treated often with multiple AHAs (including insulin).